How do in-vitro release profiles of nanosuspensions from Alzet® pumps correspond to the in-vivo situation? A case study on radiolabeled fenofibrate.

Hill, A; Breyer, S; Geissler, S; Mier, W; Haberkorn, U; Weigandt, M; Mäder, K

Hill, A; Breyer, S; Geissler, S; Mier, W; Haberkorn, U; Weigandt, M; Mäder, K.

Affiliation

Hill A; Department of Pharmacy, Institute of Pharmaceutical Technology and Biopharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, 06120 Halle/Saale, Germany.

J Control Release ; 168(1): 77-87, 2013 May 28.

Article in En | MEDLINE | ID: mdl-23499716

Subject(s)

Fenofibrate/administration & dosage; Infusion Pumps, Implantable; Animals; Drug Delivery Systems; Female; Fenofibrate/chemistry; Fenofibrate/pharmacokinetics; Iodine Isotopes/chemistry; Mice; Nanostructures; Suspensions; Tissue Distribution

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Fenofibrate / Infusion Pumps, Implantable Limits: Animals Language: En Journal: J Control Release Journal subject: FARMACOLOGIA Year: 2013 Document type: Article Affiliation country: Germany Country of publication: Netherlands

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google